|
Name |
Piperitone oxide
|
| Molecular Formula | C10H16O2 | |
| IUPAC Name* |
6-methyl-3-propan-2-yl-7-oxabicyclo[4.1.0]heptan-2-one
|
|
| SMILES |
CC(C)C1CCC2(C(C1=O)O2)C
|
|
| InChI |
InChI=1S/C10H16O2/c1-6(2)7-4-5-10(3)9(12-10)8(7)11/h6-7,9H,4-5H2,1-3H3
|
|
| InChIKey |
IAFONZHDZMCORS-UHFFFAOYSA-N
|
|
| Synonyms |
Piperitone oxide; 1,2-Epoxy-p-menthane-3-one; 5286-38-4; Pipertone, oxide; Piperitone 1-oxide; Piperitoneoxide; p-Menthan-3-one, 1,2-epoxy-; 6-methyl-3-propan-2-yl-7-oxabicyclo[4.1.0]heptan-2-one; 7-Oxabicyclo[4.1.0]heptan-2-one, 6-methyl-3-(1-methylethyl)-; 7-Oxabicyclo(4.1.0)heptan-2-one, 6-methyl-3-(1-methylethyl)-; UNII-88UA85L5VI; Piperitonoxid; Piperiton epoxid; EINECS 226-125-2; NSC 316068; p-Menthan-3-one,2-epoxy-; SCHEMBL909590; 88UA85L5VI; DTXSID1052167; 6-Methyl-3-(propan-2-yl)-7-oxabicyclo[4.1.0]heptan-2-one; NSC316068; NSC-316068; FT-0699759; 3-Isopropyl-6-methyl-7-oxabicyclo[4.1.0]heptan-2-one #; 6-Methyl-3-(1-methylethyl)-7-oxabicyclo(4.1.0)heptan-2-one
|
|
| CAS | 5286-38-4 | |
| PubChem CID | 92998 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 168.23 | ALogp: | 1.8 |
| HBD: | 0 | HBA: | 2 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 29.6 | Aromatic Rings: | 2 |
| Heavy Atoms: | 12 | QED Weighted: | 0.562 |
| Caco-2 Permeability: | -4.373 | MDCK Permeability: | 0.00002590 |
| Pgp-inhibitor: | 0 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.002 |
| 30% Bioavailability (F30%): | 0.014 |
| Blood-Brain-Barrier Penetration (BBB): | 0.893 | Plasma Protein Binding (PPB): | 61.54% |
| Volume Distribution (VD): | 1.702 | Fu: | 38.93% |
| CYP1A2-inhibitor: | 0.075 | CYP1A2-substrate: | 0.718 |
| CYP2C19-inhibitor: | 0.025 | CYP2C19-substrate: | 0.917 |
| CYP2C9-inhibitor: | 0.039 | CYP2C9-substrate: | 0.102 |
| CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.455 |
| CYP3A4-inhibitor: | 0.024 | CYP3A4-substrate: | 0.377 |
| Clearance (CL): | 14.569 | Half-life (T1/2): | 0.616 |
| hERG Blockers: | 0.012 | Human Hepatotoxicity (H-HT): | 0.339 |
| Drug-inuced Liver Injury (DILI): | 0.693 | AMES Toxicity: | 0.223 |
| Rat Oral Acute Toxicity: | 0.559 | Maximum Recommended Daily Dose: | 0.032 |
| Skin Sensitization: | 0.436 | Carcinogencity: | 0.115 |
| Eye Corrosion: | 0.948 | Eye Irritation: | 0.821 |
| Respiratory Toxicity: | 0.746 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000165 | ![]() |
0.356 | D0H1QY | ![]() |
0.271 | ||
| ENC001824 | ![]() |
0.327 | D04CSZ | ![]() |
0.245 | ||
| ENC004835 | ![]() |
0.322 | D0K7LU | ![]() |
0.227 | ||
| ENC002277 | ![]() |
0.322 | D0S3WH | ![]() |
0.222 | ||
| ENC001281 | ![]() |
0.319 | D0A2AJ | ![]() |
0.206 | ||
| ENC002065 | ![]() |
0.316 | D0C7JF | ![]() |
0.205 | ||
| ENC005928 | ![]() |
0.305 | D0U3GL | ![]() |
0.192 | ||
| ENC004915 | ![]() |
0.300 | D04ATM | ![]() |
0.188 | ||
| ENC003266 | ![]() |
0.300 | D0U4VT | ![]() |
0.188 | ||
| ENC000872 | ![]() |
0.298 | D0V8HA | ![]() |
0.185 | ||